NCT02362997View on ClinicalTrials.gov

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 26, 2021

Study Completion Date

June 30, 2023

Conditions
Hodgkin LymphomaDiffuse Large B Cell LymphomaPeripheral T-Cell Lymphoma
Interventions
DRUG

Pembrolizumab

Anti-PD-1 monoclonal antibody

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

77030

MD Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02362997 - Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL | Biotech Hunter | Biotech Hunter